Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Unité de Biologie Cellulaire de l'infection Microbienne, CNRS UMR3691, Institut Pasteur, Paris, France.
Trends Immunol. 2020 Apr;41(4):313-326. doi: 10.1016/j.it.2020.02.003. Epub 2020 Mar 6.
The enzyme type IIA secreted phospholipase A2 (sPLA2-IIA) is crucial for mammalian innate host defense against bacterial pathogens. Most studies have investigated the role of sPLA2-IIA in systemic bacterial infections, identifying molecular pathways of bacterial resistance against sPLA2-IIA-mediated killing, and providing insight into sPLA2-IIA mechanisms of action. Sensitization of (antibiotic-resistant) bacteria to sPLA2-IIA action by blocking bacterial resistance or by applying sPLA2-IIA to treat bacterial infections might represent a therapeutic option in the future. Because sPLA2-IIA is highly expressed at mucosal barriers, we also discuss how sPLA2-IIA is likely to be an important driver of microbiome composition; we anticipate that future research in this area may bring new insights into the role of sPLA2-IIA in health and disease.
IIA 型分泌型磷脂酶 A2(sPLA2-IIA)是哺乳动物先天宿主防御细菌病原体的关键酶。大多数研究都调查了 sPLA2-IIA 在全身性细菌感染中的作用,确定了细菌对 sPLA2-IIA 介导杀伤的抵抗的分子途径,并深入了解 sPLA2-IIA 的作用机制。通过阻断细菌的耐药性或应用 sPLA2-IIA 来治疗细菌感染,使(耐药性)细菌对 sPLA2-IIA 的作用敏感,这可能代表着未来的一种治疗选择。因为 sPLA2-IIA 在黏膜屏障中高度表达,我们还讨论了 sPLA2-IIA 如何可能成为微生物组组成的重要驱动因素;我们预计,该领域的未来研究可能会为 sPLA2-IIA 在健康和疾病中的作用带来新的见解。